title: [Comparison of efficacy and toxicity between gemcitabine plus carboplatin and gemcitabine plus cisplatin in the treatment of advanced non-small cell lung cancer].
abstract: BACKGROUND
  To observe the efficacy and toxicity of gemcitabine plus carboplatin (GCarb) versus gemcitabine plus cisplatin (GCis) in the treatment of advanced non-small cell lung cancer (NSCLC).
  
  
  METHODS
  Forty patients with histologically confirmed NSCLC were randomized to enter the study. GCarb group:Gemcitabine 1 000 mg/m² IV on day 1,8; carboplatin AUC 4-6 IV on day 1. GCis group: Gemcitabine 1 000 mg/m² IV on day 1,8; cisplatin 30-40 mg/m² IV on day 1-3.
  
  
  RESULTS
  The response rate was 65% and 60% for GCarb group and GCis group respectively (P > 0.5). Toxicities included myelosuppression, digestive reaction, alopecia and rash. Digestive toxicity in GCarb group was less than that in GCis group (P < 0.05).
  
  
  CONCLUSIONS
  Both GCarb and GCis regimes can be used as first-line protocol in the chemotherapy of non small cell lung cancer.
authors.affiliation: Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, Sichuan 610041, P.R.China.
authors.forename: Xiaohong
authors.initials: X
authors.lastname: Cai
authors.forename: Ping
authors.initials: P
authors.lastname: Chen
authors.forename: Xude
authors.initials: X
authors.lastname: Yin
authors.forename: Qiu
authors.initials: Q
authors.lastname: Li